Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to ...
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dolores
Source: smdailyjournal.com